The giant pharmaceuticals company operating in India, the Ranbaxy Laboratories Ltd has recently launched a new drug named the BONISTA Teriparatide injection for treating Osteoporosis. The company officials have stated that Ranbaxy has launched the drug in collaboration with the Hyderabad-based Virchow Biotech Pvt Ltd and they are the first company to launch this bio-generic product in the world.
The Senior Vice-President and Regional Director (Asia & CIS) of Ranbaxy, Mr. Sanjeev I. Dani was talking on the launching of the new drug and said, "With growing longevity, osteoporosis - a condition characterized by loss of bone mass, would gain increased attention. Ranbaxy has a number of new products in its pipeline including Bonista, for the osteoporosis patients who are normally treated by orthopaedics and gynaecologists. Bonista is also a classic example of our endeavours to offer quality biogeneric therapeutic options to doctors and an affordable and efficacious product to patients". He added that the osteoporosis segment in India is currently having a total market size of around Rs 219 crores.
|
|
|
|
|
| Posted : 4/5/2008 |
|
|
|
|
